ECSP088390A - Método para la anticoncepción hormonal preventiva bajo demanda - Google Patents

Método para la anticoncepción hormonal preventiva bajo demanda

Info

Publication number
ECSP088390A
ECSP088390A EC2008008390A ECSP088390A ECSP088390A EC SP088390 A ECSP088390 A EC SP088390A EC 2008008390 A EC2008008390 A EC 2008008390A EC SP088390 A ECSP088390 A EC SP088390A EC SP088390 A ECSP088390 A EC SP088390A
Authority
EC
Ecuador
Prior art keywords
preventive
under demand
demand
hormonal anti
conception under
Prior art date
Application number
EC2008008390A
Other languages
English (en)
Inventor
Karin Schmidt-Gollwitzer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ECSP088390A publication Critical patent/ECSP088390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se relaciona con un método de anticoncepción hormonal femenina controlada bajo demanda que comprende administrar una preparación farmacéutica que comprende al menos un gestágeno por vía transdérmica, bajo demanda y en una sola ocasión, en anticipación del encuentro sexual.
EC2008008390A 2005-10-19 2008-04-21 Método para la anticoncepción hormonal preventiva bajo demanda ECSP088390A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005050729A DE102005050729A1 (de) 2005-10-19 2005-10-19 Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption

Publications (1)

Publication Number Publication Date
ECSP088390A true ECSP088390A (es) 2008-05-30

Family

ID=37762565

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008390A ECSP088390A (es) 2005-10-19 2008-04-21 Método para la anticoncepción hormonal preventiva bajo demanda

Country Status (13)

Country Link
US (3) US20080311180A1 (es)
EP (1) EP1937275A1 (es)
JP (2) JP2009512658A (es)
KR (1) KR20080056774A (es)
CN (1) CN101340915A (es)
BR (1) BRPI0617683A2 (es)
CA (1) CA2626567C (es)
CR (1) CR9908A (es)
DE (1) DE102005050729A1 (es)
EC (1) ECSP088390A (es)
GT (1) GT200800038A (es)
HN (1) HN2008000621A (es)
WO (1) WO2007045513A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
US20120129825A1 (en) * 2009-04-14 2012-05-24 Andre Ulmann Method for on-demand contraception using levonorgestrel or norgestrel
BRPI1014035A2 (pt) * 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104797258A (zh) 2012-11-22 2015-07-22 拜耳药业股份公司 包含左炔诺孕酮和cox抑制剂的药物组合物用于按需避孕的用途和施用方法
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2999469A1 (de) 2013-05-23 2016-03-30 Bayer Pharma Aktiengesellschaft Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen ( on-demand") kontrazeption
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
CA2203541A1 (en) * 1994-10-24 1996-05-02 Kristof Chwalisz Competitive progesterone antagonists for demand-oriented female birth control
YU13902A (sh) * 1999-08-31 2006-01-16 Schering Ag. Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
WO2003093322A2 (en) * 2002-04-30 2003-11-13 The Population Council, Inc. Carrageenan based antimicrobial compositions
JP4965263B2 (ja) * 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene

Also Published As

Publication number Publication date
WO2007045513A1 (de) 2007-04-26
CA2626567A1 (en) 2007-04-26
CA2626567C (en) 2013-12-03
HN2008000621A (es) 2011-07-22
JP2009512658A (ja) 2009-03-26
CR9908A (es) 2008-05-21
EP1937275A1 (de) 2008-07-02
GT200800038A (es) 2009-04-01
US20130089574A1 (en) 2013-04-11
JP2014001239A (ja) 2014-01-09
DE102005050729A1 (de) 2007-04-26
US20070111976A1 (en) 2007-05-17
BRPI0617683A2 (pt) 2011-08-02
US20080311180A1 (en) 2008-12-18
KR20080056774A (ko) 2008-06-23
CN101340915A (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
ECSP088390A (es) Método para la anticoncepción hormonal preventiva bajo demanda
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
AR078247A1 (es) Vacuna de pcsk9
CL2008003827A1 (es) Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia..
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
AR048833A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
GT200900090A (es) Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina
CR10259A (es) Metodos para la prevencion y tratamiento de condiciones que surgen de deficiencia de estrogeno local
JOP20200260B1 (ar) مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
CO6531485A2 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
UA122873C2 (uk) Контрацептивний засіб на основі дроспіренону для пацієнтки, що страждає від надлишкової маси тіла
UA95447C2 (ru) Способ женской контрацепции
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
CU20080067A7 (es) Método para la anticoncepción hormonal preventiva bajo demanda